Current Report Filing (8-k)
December 16 2021 - 8:17AM
Edgar (US Regulatory)
0001704287
false
0001704287
2021-12-16
2021-12-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE
OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 16, 2021
Bluejay
Diagnostics, Inc.
(Exact
Name of Registrant as Specified in its Charter)
delaware
|
|
001-41031
|
|
47-3552922
|
(State
or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File No.)
|
|
(I.R.S.
Employer
Identification No.)
|
360
Massachusetts Avenue, Suite 203
Acton,
MA 01720
(Address
of principal executive offices and zip code)
(844)
327-7078
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed from last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-14(c)).
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol (s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
BJDX
|
|
The
NASDAQ Stock Market LLC
|
Item
2.02 Results of Operations and Financial Condition.
On
December 16, 2021, Bluejay Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for
the quarter ended September 30, 2021 and a corporate update. A copy of the press release is attached to this report as Exhibit 99.1
and is incorporated by reference herein.
Item
9.01. Financial Statements and Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Bluejay Diagnostics Inc.
|
|
|
|
|
By:
|
/s/ Gordon Kinder
|
|
|
Gordon Kinder
|
|
|
Chief Financial Officer
|
Dated: December 16, 2021
|
|
|
2
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From Apr 2024 to May 2024
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From May 2023 to May 2024